It should also be noted that in this clinical group of patients with metabolic disorders, different populations of CD9-positive sEVs expressing the MMP complexes, their inhibitors, and HSPs did not correlate with CD31 and VEGF-A expression in the primary tumor. This evidence concerns the gene PECAM1 and Other metabolic disease.